SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Jounce Therapeutics Inc. (JNCE)

JNCE RSS Feed
Add JNCE Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 3/8/2017 11:47:46 PM - Followers: 1 - Board type: Free - Posts Today: 0

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator (ICOS), a protein on the surface of certain T cells found in a range of solid tumors. The Company has initiated JTX-2011 multi-arm Phase I/II clinical trial in patients with solid tumors. The Company is also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. The Company is developing JTX-4014, a fully human Immunoglobulin G 4 (IgG4) monoclonal antibody.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
JNCE
Current Price
Volume:
Bid Ask Day's Range
SureTrader
JNCE News: Current Report Filing (8-k) 04/20/2017 04:14:27 PM
JNCE News: Jounce Therapeutics Initiates Phase 2 Portion of ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors 04/20/2017 04:01:00 PM
JNCE News: Current Report Filing (8-k) 04/03/2017 07:02:34 AM
JNCE News: Jounce Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes 03/31/2017 04:01:00 PM
JNCE News: Jounce Therapeutics to Present at AACR Annual Meeting on JTX-2011 Cancer Immunotherapy Program 03/22/2017 04:01:00 PM
No posts yet. Be the first!